

Clinical trials of Induction chemotherapy for Head and neck cancer in all type of patients

TrialResults-center www.trialresultscenter.org

1 docetaxel based induction CT

Trial	Treatments	Patients	Trials design and methods
TPF vs no induction chemotherapy			
Hitt (TPF) , 2005 <i>ongoing</i> n=NA follow-up:	induction chemotherapy with docetaxel + 5-FU+ cisplatin , TPF induction with docetaxel, cisplatin, 5-FU followed by chemoradiotherapy versus chemoradiotherapy	patients with locally advanced, unresectable SCCHN	open Spanish
AVENTIS-DFCI-04006 <i>ongoing</i> [NCT00095875] n=NA follow-up:	induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil followed by radiotherapy and carboplatin or docetaxel versus radiotherapy and cisplatin only	stage III or IV Histologically or cytologically confirmed squamous cell carcinoma of the head and neck	
SWOG-S0427 <i>ongoing</i> [NCT00268372] n=NA follow-up:	induction chemotherapy (docetaxel,cisplatin,5FU) with or without salvage surgery followed by chemoradiotherapy (with cisplatin) versus chemoradiotherapy (with cisplatin)	Patients With Advanced Oropharyngeal Squamous Cell Cancer	
XRP6976F₂501 <i>ongoing</i> [NCT00357149] n=NA follow-up:	Neoadjuvant Docetaxel Plus Cisplatin and 5-Fluorouracil Followed by Concomitant Chemoradiotherapy versus Chemoradiotherapy Alone	Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck	
DeCIDE (IRB 13362B, Chicago) <i>ongoing</i> [NCT00117572] n=NA follow-up:	Induction CT with docetaxel,cisplatin, fluorouracil followed by chemoradiotherapy (with docetaxel, fluorouracil, hydroxyurea) versus Chemoradiotherapy with docetaxel,fluorouracil, hydroxyurea	patients with nodal stage N2 or N3 head and neck cancer	Open
TP vs PF			
Fonseca , 2005 n=42/41 follow-up: NA	induction CT with cisplatin/docetaxel versus induction CT with cisplatin and 5-fluorouracil (PF)	patients chemotherapy-naive with locally advanced resectable and non-resectable SCCHN	Parallel groups Open Spain
TPF vs PF			

continued...

Trial	Treatments	Patients	Trials design and methods
Posner (TAX324) , 2007 [NCT00273546] n=255/246 follow-up: >24 months	induction chemotherapy consisting of docetaxel added to cisplatin/5-FU (TPF) followed by chemoradiotherapy versus standard cisplatin/5-FU (PF) induction chemotherapy followed by chemoradiotherapy	locally advanced (stage III/IV) squamous cell carcinoma of head and neck with unresectable tumor or candidates for organ preservation	Parallel groups open US, Canada, Argentina, Europe
EORTC 24971 (TAX 323) , 2006 unpublished [NCT00003888] n=177/181 follow-up: 1.75 y	induction chemotherapy with docetaxel + cisplatin + 5 FU followed by radiotherapy +/- surgery (before or after radiotherapy) versus induction chemotherapy with cisplatin + 5 FU followed by radiotherapy +/- surgery (before or after radiotherapy)	patients with stage III or IV unresectable locally advanced SCCHN	Parallel groups Open Europe
GORTEC 2000-01 [NCT00169182] n=112/108 follow-up: NA	induction chemotherapy with docetaxel + cisplatin + 5-FU versus induction chemotherapy with cisplatin + fluorouracil	patients with locally advanced larynx and hypopharynx tumors requiring initially total laryngectomy	Parallel groups open France
TAX324 (Larynx preservation subset) , 2007 [NCT00273546] n=90/76 follow-up: >24 months	induction chemotherapy consisting of docetaxel added to cisplatin/5-FU (TPF) followed by chemoradiotherapy , induction chemotherapy consisting of docetaxel added to cisplatin/5-FU (TPF) followed by chemoradiotherapy versus standard cisplatin/5-FU (PF) induction chemotherapy followed by chemoradiotherapy	locally advanced (stage III/IV) squamous cell carcinoma of larynx and hypopharynx, candidates for organ preservation	open US, Canada, Argentina, Europe
XRP6976F/2503 ongoing [NCT00261703] n=NA follow-up:	With Docetaxel-Cisplatin and 5-Fluoruracil (TPF) versus Cisplatin-5fluoruracil (PF) Followed by Concomitant Treatment With Cisplatin and Conventional Radiotherapy	Locally Advanced Squamous Cell Head and Neck Cancer, Non-Resectable	Parallel groups Open Portugal
Hitt docetaxel , 2005 ongoing n=NA follow-up:	induction chemotherapy with docetaxel + 5-FU+ cisplatin versus induction chemotherapy with 5-FU+ cisplatin	patients with locally advanced, unresectable SCCHN	Parallel groups open Spanish
Dana-Farber Cancer Institute (Posner) import ongoing [NCT00004214] n=NA follow-up:	induction CT with docetaxel, cisplatin, fluorouracil followed by chemoradiotherapy (with carboplatin) versus induction CT with cisplatin and fluorouracil followed by chemoradiotherapy (with carboplatin)	-	

References

Hitt (TPF), 2005:

R. Hitt, J. Grau, A. Lopez-Pousa, A. Berrocal, J. Sastre, J. Belon, Y. Escobar, J. Carles, H. Cortes-Funes, J. Cruz, Spanish Head and Neck Cancer Group Phase II/III Trial of Induction Chemotherapy (ICT) with Cisplatin/5-Fluorouracil (PF) vs. Docetaxel (T) plus PF (TPF) followed by Chemoradiotherapy (CRT) vs. CRT for Unresectable Locally Advanced Head and Neck Cancer (LAHNC). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 5578

R. Hitt, J. Grau, A. Lopez-Pousa, A. Berrocal, C. Garca-Giron, J. Belon, J. Sastre, J. Martinez-Trufero, H. Cortes-Funes, J. Cruz-Hernandez Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5515

AVENTIS-DFCI-04006, 0:

SWOG-S0427, 0:

XRP6976F_{2501,0} :

DeCIDE (IRB 13362B, Chicago), 0:

Fonseca, 2005:

Fonseca E, Grau JJ, Sastre J, Garcia-Gomez JM, Rueda A, Pastor M, Lara MA, Navalon M, Berrocal A, Tisaire JL, Cruz JJ Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study Eur J Cancer 2005;41:1254-60 [15908196] 10.1016/j.ejca.2005.02.019

Posner (TAX324), 2007:

Posner MR, Herchock D, Le Lann L, Devlin PM, and Haddad RI. TAX 324: A phase III trial of TPF vs PF induction chemotherapy followed by chemoradiotherapy in locally advanced SCCHN. 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007 Oct 25;357:1705-15 [17960013]

EORTC 24971 (TAX 323), 2006:

Remenar E, Van Herpen C, Lluch JG, et al A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971[Abstract] J Clin Oncol 24 (Suppl 18): A-5516, 2006

Vermorke JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desautois I, Bernier J, Lefebvre JL Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704 [17960012]

GORTEC 2000-01, 0:

Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer: preliminary results of GORTEC 2000-1. 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 5506. [0]

TAX324 (Larynx preservation subset), 2007:

XRP6976F/2503, 0:

Hitt docetaxel, 2005:

Hitt R, Grau JJ, Lopez-Pousa A, et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs CRT alone for unresectable locally advanced head and neck cancer 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 5515 [0]

R. Hitt, J. Grau, A. Lopez-Pousa, A. Berrocal, C. Garca-Giron, J. Belon, J. Sastre, J. Martinez-Trufero, H. Cortes-Funes, J. Cruz-Hernandez Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5515

2 induction polyCT with platin

Trial	Treatments	Patients	Trials design and methods
MEPFL vs no induction chemotherapy			
National Health Research Institutes, Taiwan <i>ongoing</i> [NCT00201396] n=NA follow-up:	Induction MEPFL (Mitomycin C, Epirubicin, Cisplatin, 5-Fluorouracil, Leucovorin) three cycles followed with weekly cisplatin concurrently with radiotherapy versus Weekly cisplatin concurrently with radiotherapy	Patients with advanced nasopharyngeal Carcinoma stage IVA (T4) and/or IVB (N3) but without distant metastasis	
polyCT with platin vs no induction chemotherapy			
Kohno , 2000 n=13/11 follow-up: 5.6y (5-6.6y)	induction chemotherapy with cisplatin, etoposide, mitomycin-C followed by surgery versus surgery alone	patients with previously untreated stage III and IV resectable squamous cell carcinoma of the oral cavity and pharynx	Parallel groups Open Japan
Maipang (Songkla) , 1995 n=30/24 follow-up: NA	induction chemotherapy + surgery + post operative radiotherapy versus surgery + post operative radiotherapy	advanced stage III and IV SCCHN with resectable tumor	Parallel groups open Thailand
Mazon (Crteil-82) , 1992 n=55/61 follow-up: NA	induction chemotherapy (bleomycin, methotrexate, 5-fluorouracil, cisplatin) + locoregional treatment (+/- surgery + radiotherapy) versus locoregional treatment alone (+/- surgery + radiotherapy)	Stage II-IV squamous cell carcinoma of the oropharynx or oral cavity	Parallel groups Open france
Jaulerry Trial 2 (Curie)(HNCGIC03) , 1992 n=55/53 follow-up: 2.5 y (0.83-3.4y)	induction chemotherapy (cisplatin,5FU, vindesine) + radiotherapy +/- surgery versus radiotherapy	T3, T4 tumors of the oropharynx, hypopharynx, larynx, oral cavity and T2 hypopharynx	Parallel groups Open france
Salvajoli (AC Camargo) , 1992 n=30/30 follow-up: 2.3y median	induction chemotherapy (vinblastine, mitomycin, cisplatin, bleomycin) and radiotherapy (70 Gy) versus radiotherapy alone (70 Gy)	Patients with unresectable stage IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx	Parallel groups open Brazil
Brunin (HNCGIC02) , 1989 n=48/52 follow-up: 2.9y median, range 1.2-4.6	induction chemotherapy (cisplatin, bleomycin, vindesine, mitomycin) prior radiotherapy (55 Gy) +/- surgery versus radiotherapy (55 Gy) +/- surgery alone	stage III and IV carcinomas of the oral cavity, oropharynx and larynx and stage II carcinomas of the hypopharynx	Parallel groups open France

continued...

Trial	Treatments	Patients	Trials design and methods
Schuller (SWOG 8006) , 1988 n=82/76 follow-up: median 5y	induction chemotherapy, surgery and post operative radiotherapy versus surgery and post operative radiotherapy	operable stage III-IV epidermoid carcinoma of the head and neck	Parallel groups open US
Szpirglas (Piti-81) , 1988 n=NA	-	-	
Carugati (Buenos Aires) , 1988 n=82/38 follow-up: 5 y	induction chemotherapy before radical treatment versus radical treatment	stage III and IV of SSC of the oral cavity, larynx, oropharynx	Parallel groups open Argentina
HNCP , 1987 n=140/152 follow-up: median 5.1y (range 3.1-6.6)	induction chemotherapy (cisplatin + bleomycin) + surgery + postoperative radiotherapy versus surgery + radiotherapy	resectable stage III or IV cancers of the oral cavity, larynx or hypopharynx	Parallel groups open US
polyCT with platin vs cisplatin			
Chauvergne , 1988 n=122/119 follow-up:	cisplatin, vincristin, methotrexate, bleomycin versus cisplatin alone	unresectable advanced squamous cell carcinoma of head and neck	Parallel groups open france

References

National Health Research Institutes, Taiwan, 0:

Kohno, 2000:

Kohno N, Ikari T, Kawaida M, Tanaka K, Kawaura M, Kano S, Nakamizo M Survival results of neoadjuvant chemotherapy for advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2000 Jun;30:253-8 [10939428]

Maipang (Songkla), 1995:

Maipang T, Maipang M, Geater A, Panjapiyakul C, Watanaarepornchai S, Punperk S Combination chemotherapy as induction therapy for advanced resectable head and neck cancer J Surg Oncol 1995;59:80-5 [7539873]

Mazeron (Crteil-82), 1992:

Mazeron JJ, Martin M, Brun B, Grimard L, Lelievre G, Vergnes L, Haddad E, Feuilhade F, Piedbois P, Strunski W Induction chemotherapy in head and neck cancer: results of a phase III trial Head Neck 1992;14:85-91 [1376306]

Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D, Pontvert D, Validire P, Zafrani B, Blaszk B Induction chemotherapy in advanced head and neck tumors: results of two randomized trials Int J Radiat Oncol Biol Phys 1992;23:483-9 [1612948]

Jaulerry Trial 2 (Curie)(HNCGIC03), 1992:

Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D, Pontvert D, Validire P, Zafrani B, Blaszk B Induction chemotherapy in advanced head and neck tumors: results of two randomized trials Int J Radiat Oncol Biol Phys 1992;23:483-9 [1612948]

Brunin F, Rodriguez J, Jaulerry C, Mosseri V, Jouve M, Point D, Asselain B, Validire P, Blaszk B, Zafrani B [Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients] Bull Cancer 1992;79:893-904 [1283088]

Salvajoli (AC Camargo), 1992:

Salvajoli JV, Morioka H, Trippe N, Kowalski LP A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma Eur Arch Otorhinolaryngol 1992;249:211-5 [1642879]

Brunin (HNCGIC02), 1989:

Brunin F, Rodriguez J, Jaulerry C, Jouve M, Pontvert D, Point D, Mosseri V, Pouillart P, Asselain B, Brugere J Induction chemotherapy in advanced head and neck cancer. Preliminary results of a randomized study *Acta Oncol* 1989;28:61-5 [2650723]

Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D, Pontvert D, Validire P, Zafrani B, Blaszk B Induction chemotherapy in advanced head and neck tumors: results of two randomized trials *Int J Radiat Oncol Biol Phys* 1992;23:483-9 [1612948]

Brunin F, Rodriguez J, Jaulerry C, Mosseri V, Jouve M, Point D, Asselain B, Validire P, Blaszk B, Zafrani B [Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients] *Bull Cancer* 1992;79:893-904 [1283088]

Schuller (SWOG 8006), 1988:

Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group *Laryngoscope* 1988;98:1205-11 [3054373]

Szpirglas (Piti-81), 1988:

Szpirglas H, Nizri D, Marneur M, et al. Neoadjuvant chemotherapy.A randomized trial before radiotherapy in oral and oropharyngealcarcinomas: end results In: *Proceedings of the 2nd international headand neck oncology research conference*. Kugler, Ghedini Editore, 1988: 26164.

Carugati (Buenos Aires), 1988:

Carugati A, Pradier R, de la Torre A. Combination chemotherapypreradicaltreatment for head and neck squamous cell carcinoma *Proc ASCO* 1988; 7: 152 *HNCP*, 1987:

Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program *Cancer* 1987;60:301-11

Jacobs C, Makuch R Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program *J Clin Oncol* 1990;8:838-47 [2185340]

Chauvergne, 1988:

Chauvergne J, Cappelaere P, Clavel B, David M, Fargeot P, Meeus L, Traissac L, Klein T [Randomized trial of initial chemotherapy with cisplatin alone or in combination in 241 advanced carcinomas of the upper respiratory and digestive tract] *Ann Otolaryngol Chir Cervicofac* 1988;105:581-9 [2470310]

3 induction polyCT without platin

Trial	Treatments	Patients	Trials design and methods
polyCT without platin vs no induction chemotherapy			
Richard (EORTC 78-OCP) , 1991 n=112/110 follow-up: median 5y (range 1-9y)	intraarterial induction chemotherapy (vincristine, bleomycin) + surgery + post operative radiotherapy versus surgery + post operative radiotherapy	Squamous cell carcinoma of the oral cavity and oropharynx	Parallel groups open europe
Jortay (EORTC 24771) , 1990 n=89/98 follow-up: 5y mean	induction chemotherapy with vincristine, bleomycin, methotrexate followed by surgery +/- radiotherapy versus surgery +/- radiotherapy	operable epidermoid carcinoma of the pyriform sinus	Parallel groups open France, Italy
Holoye (MCW-1) , 1985 n=43/40 follow-up: at least 2y post diagnosis	induction chemotherapy (bleomycin, cytoxan, MTX, 5FU) + standard treatment (preoperative radiotherapy followed by surgery) versus standard treatment (preoperative radiotherapy followed by surgery)	Stage III and IV squamous cell carcinoma of oral cavity, oropharynx, nasopharynx, nasal cavity or paranasal sinuses, larynx hypopharynx and stage II of pyriform sinus	Parallel groups open US

References

Richard (EORTC 78-OCP), 1991:

Richard JM, Kramar A, Molinari R, Lefebvre JL, Blanchet F, Jortay A, Sancho-Garnier H Randomised EORTC head and neck cooperative group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma Eur J Cancer 1991;27:821-7 [1718348]

Jortay (EORTC 24771), 1990:

Jortay A, Demard F, Dalesio O, Blanchet C, Desaulty A, Gehanno C, Lefebvre JL, Molinari R, Traissac L, Dehesdin M A randomized EORTC study on the effect of preoperative polychemotherapy in pyriform sinus carcinoma treated by pharyngolaryngectomy and irradiation. Results from 5 to 10 years Acta Chir Belg 1990;90:115-22 [1695801]

Holoye (MCW-1), 1985:

Holoye PY, Grossman TW, Toohill RJ, Kun LE, Byhardt RW, Duncavage JA, Teplin RW, Ritch PS, Hoffman RG, Malin TC Randomized study of adjuvant chemotherapy for head and neck cancer Otolaryngol Head Neck Surg 1985;93:712-7 [2418400]

Kun LE, Toohill RJ, Holoye PY, Duncavage JA, Byhardt RW, Ritch PS, Grossman TW, Hoffmann RG, Cox JD, Malin T, A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 1986;12:173-8.

4 Larynx preservation

Trial	Treatments	Patients	Trials design and methods
TPF vs PF Posner (TAX324) , 2007 [NCT00273546] n=255/246 follow-up: >24 months	induction chemotherapy consisting of docetaxel added to cisplatin/5-FU (TPF) followed by chemoradiotherapy versus standard cisplatin/5-FU (PF) induction chemotherapy followed by chemoradiotherapy	locally advanced (stage III/IV) squamous cell carcinoma of head and neck with unresectable tumor or candidates for organ preservation	Parallel groups open US, Canada, Argentina, Europe
EORTC 24971 (TAX 323) , 2006 unpublished [NCT00003888] n=177/181 follow-up: 1.75 y	induction chemotherapy with docetaxel + cisplatin + 5 FU followed by radiotherapy +/- surgery (before or after radiotherapy) versus induction chemotherapy with cisplatin + 5 FU followed by radiotherapy +/- surgery (before or after radiotherapy)	patients with stage III or IV unresectable locally advanced SCCHN	Parallel groups Open Europe
GORTEC 2000-01 [NCT00169182] n=112/108 follow-up: NA	induction chemotherapy with docetaxel + cisplatin + 5-FU versus induction chemotherapy with cisplatin + fluorouracil	patients with locally advanced larynx and hypopharynx tumors requiring initially total laryngectomy	Parallel groups open France

continued...

Trial	Treatments	Patients	Trials design and methods
TAX324 (Larynx preservation subset) , 2007 [NCT00273546] n=90/76 follow-up: >24 months	induction chemotherapy consisting of docetaxel added to cisplatin/5-FU (TPF) followed by chemoradiotherapy , induction chemotherapy consisting of docetaxel added to cisplatin/5-FU (TPF) followed by chemoradiotherapy versus standard cisplatin/5-FU (PF) induction chemotherapy followed by chemoradiotherapy	locally advanced (stage III/IV) squamous cell carcinoma of larynx and hypopharynx, candidates for organ preservation	open US, Canada, Argentina, Europe
XRP6976F/2503 <i>ongoing</i> [NCT00261703] n=NA follow-up:	With Docetaxel-Cisplatin and 5-Fluoruracil (TPF) versus Cisplatin-5fluoruracil (PF) Followed by Concomitant Treatment With Cisplatin and Conventional Radiotherapy	Locally Advanced Squamous Cell Head and Neck Cancer, Non-Resectable	Parallel groups Open Portugal
Hitt docetaxel , 2005 <i>ongoing</i> n=NA follow-up:	induction chemotherapy with docetaxel + 5-FU+ cisplatin versus induction chemotherapy with 5-FU+ cisplatin	patients with locally advanced, unresectable SCCHN	Parallel groups open Spanish
Dana-Farber Cancer Institute (Posner) import <i>ongoing</i> [NCT00004214] n=NA follow-up:	induction CT with docetaxel, cisplatin, fluorouracil followed by chemoradiotherapy (with carboplatin) versus induction CT with cisplatin and fluorouracil followed by chemoradiotherapy (with carboplatin)	-	
induction PF vs surgery			
GETTEC , 1998 n=NA follow-up: median 5 y	induction chemotherapy with cisplatin and fluorouracil, followed by radiotherapy in good responders, and by total laryngectomy plus radiotherapy in poor responders versus total laryngectomy followed by radiotherapy	advanced (T3) larynx carcinoma considered for total laryngectomy	Parallel groups Open France
Veterans Affairs , 1998 n=NA follow-up: 2.75y median (0.9-5.2)	three cycles of chemotherapy (cisplatin and fluorouracil) and definitive radiotherapy versus conventional laryngectomy and postoperative surgery	stage III and IV previously untreated carcinoma of the larynx	Parallel groups open USA

continued...

Trial	Treatments	Patients	Trials design and methods
EORTC 24891 , 1996 [EORTC 24891] n=100/94 follow-up: 4.25 years median (0.25-8.8)	induction chemotherapy with cisplatin plus fluorouracil + radiotherapy or surgery + post operative surgery versus total laryngectomy + postoperative radiotherapy	squamous cell carcinomas of the pyriform sinus or aryepiglottic fold	Parallel groups open Europe

References

Posner (TAX324), 2007:

Posner MR, Herchok D, Le Lann L, Devlin PM, and Haddad RI. TAX 324: A phase III trial of TPF vs PF induction chemotherapy followed by chemoradiotherapy in locally advanced SCCHN. 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta

Posner MR, Herschok DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Racz LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007 Oct 25;357:1705-15 [[17960013](#)]

EORTC 24971 (TAX 323), 2006:

Remenar E, Van Herpen C, Lluch JG, et al A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971[Abstract] J Clin Oncol 24 (Suppl 18): A-5516, 2006

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desauois I, Bernier J, Lefebvre JL Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704 [[17960012](#)]

GORTEC 2000-01, 0:

Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer: preliminary results of GORTEC 2000-1. 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 5506. [[0](#)]

TAX324 (Larynx preservation subset), 2007:

XRP6976F/2503, 0:

Hitt docetaxel, 2005:

Hitt R, Grau JJ, Lopez-Pousa A, et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs CRT alone for unresectable locally advanced head and neck cancer 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 5515 [[0](#)]

R. Hitt, J. Grau, A. Lopez-Pousa, A. Berrocal, C. Garca-Giron, J. Belon, J. Sastre, J. Martinez-Trufero, H. Corts-Funes, J. Cruz-Hernandez Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5515

Dana-Farber Cancer Institute (Posner) import, 0:

GETTEC, 1998:

Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, Stromboni-Luboinski M, Hill C Randomized trial of induction chemotherapy in larynx carcinoma Oral Oncol 1998;34:224-8 [[9692058](#)]

Veterans Affairs, 1998:

Hillman RE, Walsh MJ, Wolf GT, Fisher SG, Hong WK Functional outcomes following treatment for advanced laryngeal cancer. Part I–Voice preservation in advanced laryngeal cancer. Part II–Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group Ann Otol Rhinol Laryngol Suppl 1998;172:1-27 [[9597955](#)]

Terrell JE, Fisher SG, Wolf GT Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1998 Sep;124:964-71 [9738804]

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991 Jun 13;324:1685-90 [2034244]
EORTC 24891, 1996:

Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahnoud T Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group J Natl Cancer Inst 1996;88:890-9 [8656441]

Lefebvre JL, Chevalier D, Luboinski B, et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial J Clin Oncol 2004; 22 (Suppl 14): A-5531

5 other induction CT

Trial	Treatments	Patients	Trials design and methods
CT with methotrexate vs no induction chemotherapy			
Fazekas (RTOG 6801) , 1980 n=312/326 follow-up: 1.67y mean	induction chemotherapy with methotrexate followed by radiotherapy +/- post radiotherapy surgery versus radiotherapy alone +/- post radiotherapy surgery	locally advanced squamous cell carcinoma or lymphoepithelioma of the oral cavity, oropharynx, supraglottic larynx or hypopharynx	Parallel groups open US
Richard (IGR-65) , 1974 n=21/18 follow-up: 5 years at least	Intra arterial infusion chemotherapy with methotrexate followed by radiotherapy versus radiotherapy alone	advanced cancer (T4) of the oral cavity and oropharynx	Parallel groups Open France
PBM vs PF			
Clark (Dana farber cancer Institute 83-084) , 1988 n=55/55 follow-up:	induction chemotherapy with bleomycin, cisplatin, LTX, leucovorin (PBM) followed by local treatment (surgery and/or radiotherapy) versus induction chemotherapy with cisplatin, 5FU followed by local treatment (surgery and/or radiotherapy)	patients with previously untreated stage III and IV squamous cell carcinomas of head and neck (SCCHN)	Parallel groups open US
VP16 based CT vs PF			
Prvost , 2005 n=99/98 follow-up: NA	induction chemotherapy with cisplatin+VP16 + radiotherapy versus induction chemotherapy with cisplatin+5-FU+ radiotherapy	patient with unresectable advanced head and neck cancer	Parallel groups open France

References

Fazekas (RTOG 6801), 1980:

Fazekas JT, Sommer C, Kramer S Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity,

oropharynx, supraglottic larynx or hypopharynx Int J Radiat Oncol Biol Phys 1980;6:533-41 [7410127]

Kramer S Methotrexate and radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, oropharynx, supraglottic larynx, and hypopharynx. (Preliminary report of a controlled clinical trial of the Radiation Therapy Oncology Group). Can J Otolaryngol 1975;4:213-8 [1139418]
Richard (IGR-65), 1974:

Richard JM, Sancho H, Lepintre Y, Rodary J, Pierquin B Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx Cancer 1974;34:491-6 [4852531]

Clark (Dana farber cancer Institute 83-084), 1988:

Clark JR, Fallon BG, Dreyfuss AI, Norris CM Jr, Anderson JW, Ervin TJ, Anderson RF, Chaffey JT, Miller D, Frei E 3rd Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer Semin Oncol 1988;15:35-44 [3393916]

Prvost, 2005:

Prevost A, Merol JC, Aime P, Moutel K, Roger-Liautaud F, Nasca S, Legros M, Coninx P A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck Oncol Rep 2005;14:771-6 [16077990]

6 paclitaxel based induction CT

Trial	Treatments	Patients	Trials design and methods
paclitaxel based CT vs PF			
Hitt paclitaxel , 2005 n=189/193 follow-up: 1.93y (0.025-5y)	induction chemotherapy with paclitaxel, cisplatin, and fluorouracil versus induction chemotherapy with cisplatin and FU	locally advanced head and neck cancer	Parallel groups Open Spain

References

Hitt paclitaxel, 2005:

Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Marti JL, Lobo F, Pastor P, Valenti V, Belon J, Sanchez MA, Chaib C, Pallares C, Anton A, Cervantes A, Paz-Ares L, Cortes-Funes H Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 2005;23:8636-45 [16275937]
10.1200/JCO.2004.00.1990

7 PF induction CT

Trial	Treatments	Patients	Trials design and methods
PF vs no induction chemotherapy			
Dalley (AHNTG) , 1995 n=140/140 follow-up: 4.8y	induction chemotherapy with cisplatin, fluorouracil followed by definitive local therapy versus definitive local therapy alone	locally advanced untreated squamous cell carcinoma of head and neck	Parallel groups open Australia

continued...

Trial	Treatments	Patients	Trials design and methods
Licitra , 2003 [NCT00002747] n=98/97 follow-up: 6.3 y median	induction chemotherapy with cisplatin and fluorouracil followed by surgery +/- radiotherapy versus surgery alone +/- radiotherapy	resectable untreated oral cavity squamous cell carcinoma	Parallel groups Open Italy
RTOG 91-11 (I+RT vs RT alone) , 2003 n=173/173 follow-up: 6.9y (median)	induction cisplatin plus fluorouracil followed by radiotherapy, versus radiotherapy alone	locally advanced cancer of the larynx requiring total laryngectomy	Parallel groups Open USA
Hareyama , 2002 n=40/40 follow-up: 4.08 y (median) (range 0.3-9.2)	two courses of chemotherapy, consisting of cisplatin and 5-fluorouracil (CDDP-5FU), that were administered before radiation therapy versus radiotherapy alone	locoregional carcinoma of the nasopharynx	Parallel groups Open Japan
Domenge (GETTEC) , 2000 n=157/161 follow-up: 5y median	induction chemotherapy with cisplatin plus fluorouracil followed by loco-regional treatment consisted either of surgery plus radiotherapy or of radiotherapy alone versus locoregional treatment consisted either of surgery plus radiotherapy or of radiotherapy alone	Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible	Parallel groups Open France
Lewin (SHNG-85) , 1997 n=215/208 follow-up: 4.5y mean, 1.5-8y	induction chemotherapy (Cisplatin, 5 FU) followed by radiotherapy +/- surgery versus radiotherapy alone +/- surgery	Patients with non resectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx, stage III to IV, or with resectable and non resectable tumor of the oral cavity stage II to IV	Parallel groups open Denmark, Norway, Sweden
Gedouin (Rennes-87) , 1996 n=57/64 follow-up: 5y median	induction chemotherapy (cisplatin + 5FU) before regional treatment versus regional treatment alone	patients with squamous cell carcinoma of hypopharynx and base of tongue	Parallel groups open France
Hasegawa (HNAP-02) , 1996 n=25/25 follow-up: 3.7y	2 cycles of neoadjuvant CT: CDDP (70mg/m2, day 1) and 5FU (660mg/m2, day 2-6) followed by surgery versus surgery (without preoperative treatment)	patients with resectable previously untreated advanced head and neck squamous cell carcinoma (stage III/IV M0)	
Domenge (GETTEC neo1) , 1995 n=83/83 follow-up: median 3y	induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy versus radiotherapy	oropharyngeal tumor	Parallel groups open France

continued...

Trial	Treatments	Patients	Trials design and methods
Di Blasio (Parma) , 1994 n=35/31 follow-up: median 4y (1.9-6.25)	induction chemotherapy with cisplatin, fluorouracil followed by locoregional treatment versus locoregional treatment alone	stage II-IV resectable head and neck cancer	Parallel groups open Italy
Volling (Cologne) , 1994 n=48/47 follow-up: 1.75y (range 1-2y)	Induction chemotherapy (carboplatin, 5-FU) + surgery + postoperative radiotherapy versus surgery + postoperative radiotherapy	resectable stage T2-T3, N0-N2 carcinomas of oral cavity, oro- and hypopharynx and a performance status of at least 2	Parallel groups Open Deutschland
Paccagnella (GSTTC-86) , 1994 n=118/119 follow-up: median 12.5 y range 10.7-14,6	four cycles of cisplatin and 5-fluorouracil followed by locoregional treatment versus locoregional treatment alone	histologically proven squamous cell carcinoma of the hypopharynx, oropharynx, oral cavity, or paranasal sinus; stage III or IV disease without distant metastases	Parallel groups open Italy
Depondt (CFHNS) , 1993 n=NA follow-up: 2.1y	carboplatin 400mg/m2 x3, fluorouracil 5000mg/m2 x3 versus RT or S+RT	patients with head and neck cancer	Parallel groups France
Tejedor (Las Palmas) , 1992 n=19/17 follow-up: 1y minimum	three courses of induction chemotherapy followed by radiotherapy versus radiotherapy alone	Patients with locally advanced squamous cell carcinoma of the head and neck, stages III-IV, M0	Parallel groups Open Spain
Toohill (MCW-2) , 1987 n=27/33 follow-up: 24-44 months	induction chemotherapy (cisplatin, fluorouracil) + radiotherapy (50 Gy) + surgery versus radiotherapy (50 Gy) + surgery	advanced squamous cell carcinoma of the upper aerodigestive tract	Parallel groups Open US
BNH 003 unpublished n=NA follow-up: NA	cisplatin 100mg/m2 x2-3, 5 fluorouracil 4000 mg/m2 x2-3 versus surgery + radiotherapy	-	
EORTC 24844 unpublished [EORTC-24844] n=74/65 follow-up: NA	Induction Chemotherapy with Cisplatin and fluorouracil followed by Surgery followed by Radiotherapy versus Surgery followed by Radiotherapy	Advanced Squamous Cell Carcinoma of the Lateral Oropharynx and Lateral Posterior Oral Cavity	Parallel groups Open
Hitt (PF) , 2005 ongoing n=NA follow-up:	induction chemotherapy with docetaxel + 5-FU+ cisplatin , PF induction followed by chemoradiotherapy versus chemoradiotherapy	patients with locally advanced, unresectable SCCHN	open Spanish

carboplatin, 5FU vs PF

continued...

Trial	Treatments	Patients	Trials design and methods
De Andres , 1995 n=46/49 follow-up: minimum 5y	induction chemotherapy with carboplatin and fluorouracil versus induction chemotherapy with cisplatin and fluorouracil	stage IV-M0 head and neck cancer	Parallel groups open Spain
PF with leucovorin vs PF	without leucovorin		
Fonseca , 1997 n=18/21 follow-up: NA	induction chemotherapy with cisplatin,5FU and leucovorin versus induction chemotherapy with cisplatin and 5FU	Stage III-IVa locally advanced head and neck cancer	Parallel groups Open Spain

References

Dalley (AHNTG), 1995:

Dalley D, Beller E, Aroney R, et al. The value of chemotherapy (CT) prior to definitive local therapy (DTL) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN) Proc ASCO 1995; 14: 297

Licitra, 2003:

Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantu G Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003;21:327-33 [[1252526](#)]

RTOG 91-11 (I+RT vs RT alone), 2003:

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 2003;349:2091-8 [[14645636](#)] [10.1056/NEJMoa031317](#)

Forastiere AA, Mauro M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx: induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta [0]

Hareyama, 2002:

Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma Cancer 2002;94:2217-23 [[12001120](#)] [10.1002/cncr.10473](#)

Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, Marandas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC) Br J Cancer 2000;83:1594-8 [[11189100](#)] [10.1054/bjoc.2000.1512](#)

Lewin (SHNG-85), 1997:

Lewin F, Damber L, Jonsson H, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Int J Radiat Oncol 1997;43: 2328

Gedouin (Rennes-87), 1996:

Gedouin D, Desprez P, Perron JJ, Fleury F, Leclech G, Miglianico L, Belpomme D, Chenal C [Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment] Bull Cancer Radiother 1996;83:104-7 [[8688215](#)]

Hasegawa (HNAP-02), 1996:

Hasegawa Y, Matsuura H, Fukushima M, Kano M, Shimozato K. Potential suppression of distant and node metastasis by neoadjuvant chemotherapy in advanced head and neck cancer: result of a randomized trial Proc ASCO 1996; 15: 318.

Hasegawa Y et al. Proc ASCO 1994;13:286

Domenge (GETTEC neo1), 1995:

Domenge C, Lancar R, Coche-Dequean B, et al. Induction chemotherapy before radiotherapy in oropharyngeal carcinoma: a randomized trial *Eur J Cancer* 1995; 31A (suppl 6): S86

Di Blasio (Parma), 1994:

Di Blasio B, Barbieri W, Bozzetti A, Iotti C, Di Sarra S, Cocconi G. A prospective randomized trial in resectable head and neck carcinoma: loco-regional treatment with and without neoadjuvant chemotherapy *Proc ASCO* 1994; 13: 279

Volling (Cologne), 1994:

Volling P, Schröder M, Müller RP, Ebeling O, Quirin R, Stennert E. Induction chemotherapy in primary resectable head and neck tumors: a prospective randomized trial *Int J Oncol* 1994; 4: 90914

Volling P, Schröder M, Eckel H, Ebeling O, Stennert E [Results of a prospective randomized trial with induction chemotherapy for cancer of the oral cavity and tonsils] *HNO* 1999;47:899-906 [[10550374](#)]

Volling P, Schröder M [Preliminary results of a prospective randomized study of primary chemotherapy in carcinoma of the oral cavity and pharynx] *HNO* 1995;43:58-64 [[7713766](#)]

Paccagnella (GSTTC-86), 1994:

Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo *J Natl Cancer Inst* 1994;86:265-72 [[8158680](#)]

Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, Boldrin F, Marchiori C, Lunghi F, Fede A, Bordin A, Da Mosto MC, Sileni VC, Orlando A, Jirillo A, Tomio L, Pappagallo GL, Ghi MG Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up *J Natl Cancer Inst* 2004;96:1714-7 [[15547184](#)] [10.1093/jnci/djh306](#)

Depondt (CFHNS), 1993:

Depondt J, Gehanno P, Martin M, Lelievre G, Guerrier B, Peytral C, Schott H, Pellae-Cosset B Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer *Oncology* 1993;50 Suppl 2:23-7 [[8233298](#)]

Tejedor (Las Palmas), 1992:

Tejedor M, Murias A, Soria P, Aguiar J, Salinas J, Hernandez MA, Molano F, Gonzalez G Induction chemotherapy with carboplatin and fluorouracil in advanced head and neck cancer. A randomized study *Am J Clin Oncol* 1992;15:417-21 [[1524042](#)]

Toohill (MCW-2), 1987:

Toohill RJ, Anderson T, Byhardt RW, Cox JD, Duncavage JA, Grossman TW, Haas CD, Haas JS, Hartz AJ, Libnoch JA Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report *Arch Otolaryngol Head Neck Surg* 1987;113:758-61 [[3580158](#)]

BNH 003, 0:

Pignon JP, Bourhis J, Domenge C, Designe L Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer *Lancet* 2000;355:949-55 [[10768432](#)]

EORTC 24844, 0:

Pignon JP, Bourhis J, Domenge C, Designe L Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer *Lancet* 2000;355:949-55 [[10768432](#)]

Hitt (PF), 2005:

R. Hitt, J. Grau, A. Lopez-Pousa, A. Berrocal, J. Sastre, J. Belon, Y. Escobar, J. Carles, H. Cortes-Funes, J. Cruz, Spanish Head and Neck Cancer Group Phase II/III Trial of Induction Chemotherapy (ICT) with Cisplatin/5-Fluorouracil (PF) vs. Docetaxel (T) plus PF (TPF) followed by Chemoradiotherapy (CRT) vs. CRT for Unresectable Locally Advanced Head and Neck Cancer (LAHNC). *Journal of Clinical Oncology*, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 5578

R. Hitt, J. Grau, A. Lopez-Pousa, A. Berrocal, C. Garca-Giron, J. Belon, J. Sastre, J. Martinez-Trufero, H. Cortes-Funes, J. Cruz-Hernandez Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5515

De Andres, 1995:

De Andres L, Brunet J, Lopez-Pousa A, Burgues J, Vega M, Tabernero JM, Mesia R, Lopez JJ Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer J Clin Oncol 1995;13:1493-500 [[7751897](#)]
Fonseca, 1997:

Fonseca E, Cruz JJ, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, Munoz A, Pardal JL Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer Ann Oncol 1997;8:713-4 [[9296230](#)]

8 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.